Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.
NCT00632125
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
1695
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Kidney Disease
Interventions
DRUG:
HX575 recombinant human erythropoietin alfa
Sponsor
Sandoz
Collaborators
[object Object]